Figure 3From: Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells Gemcitabine release profiles from PLGem and GemPo. Gemcitabine release profiles from (A) PLGem and (B) GemPo nanoparticles were evaluated in PBS or human pancreatic carcinoma (PANC1) cell lysates. Values on the Y-axis represent the amount of Gemcitabine released from the nanoparticles in a defined volume.Back to article page